LONDON, UK, Wednesday 12 November 2014, 07:00 GMT – Norgine B.V. today announced new data which demonstrate that bowel cleanser MOVIPREP® (2L polyethylene glycol + ascorbate), in a German colorectal cancer screening population, may lead to reduced long-term colorectal cancer treatment costs. The study will be presented today at the International Society for Pharmacoeconomics and Outcomes Research 17th Annual European Congress (ISPOR) in Amsterdam, The Netherlands.
The study evaluates the clinical and economic impact of bowel cleansing quality, using efficacy rates of colorectal cancer screening and subsequent cost of treating colorectal cancer in a cohort of patients undergoing screening colonoscopy in Germany (MODEC, n=394). Patients were randomised to receive either 2L MOVIPREP® (PEG+ASC, n=201) or sodium picosulfate/magnesium citrate (NaPic/MgCit, n=193). The total cost of colonoscopy and the treatment of subsequent colorectal cancer were modelled over a 10 year period in a cohort of 10,000 patients entering the model at age 55 years.
Results from the study show that the cleansing quality of MOVIPREP® is greater than NaPic/MgCit for all segments of the colon (98.0% vs. 57.5%, p<0.0001).2The long-term cost consequence model also predicts that while the use of MOVIPREP® vs. NaPic/MgCit increases the average per-patient cost associated with colonoscopy by €67, MOVIPREP® enables better bowel cleansing which permits the early detection of polyps and adenomas resulting in less progression to colorectal cancer and an average per-patient saving in colorectal cancer treatment costs of €488. The cost consequence model predicts an average overall cost saving of €420 per patient over a 10 year period.
Peter Martin, Chief Operating Officer, Norgine, commented: “The cost of treatment should always be balanced against its long-term potential to benefit patients. This study demonstrates not only the superior bowel cleansing ability of MOVIPREP®, which could help result in fewer cases of colorectal cancer progressing through earlier detection, but also the projected treatment cost saving that health systems could benefit from by using this effective two litre formulation.”
Colorectal cancer is the third most common cancer worldwide and accounts for every seventh case of cancer in Germany., Screening programmes have reduced the number of deaths caused by colorectal cancer, but the detection and removal of polyps/adenomas during colonoscopy can often be suboptimal.
MOVIPREP® was originally developed by Norgine. It is available in Europe and Australia through Norgine’s own infrastructure and in Eastern Europe, the US, India, Japan and Canada via partners. Additionally, The Ministry of Health of the Russian Federation granted approval for MOVIPREP® in Russia on 22 September 2014.
Notes to Editors
Charlotte Andrews: Tel: +44 (0)1895 453669, Mob: +44 (0)7714 061485
Peter Martin: Tel: +44 (0)1895 453744, Mob: +44 (0)7799 078744
Follow us @Norgine
About the study presented at ISPOR
The degree of benefit from colonoscopy in the prevention of colorectal cancer (CRC) is highly dependent on the quality of bowel cleansing. In a randomized study of patients undergoing screening colonoscopy in Germany (MODEC), 2L polyethylene glycol with electrolytes + ascorbate components (PEG+ASC) resulted in numerically higher overall polyp/adenoma detection rates (PDR/ADR) and significantly higher right-sided PDR/ADR than sodium picosulfate/magnesium citrate (NaPic/MgCit), together with better bowel cleansing. The objective of the model was to examine the socioeconomic impact of bowel cleansing quality on the effectiveness of CRC screening in the eligible German population.
MOVIPREP® (2L polyethylene glycol + ascorbate) is a bowel preparation indicated for bowel cleansing prior to any clinical procedures requiring a clean bowel, e.g. bowel endoscopy or radiology. MOVIPREP® is a registered trademark of the Norgine group of companies.
Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2013, Norgine’s total revenue was €274 million and the company employs over 1,000 people.
Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients. Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.
Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns an R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.
For more information, please visit www.norgine.com
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com
NORGINE and the sail logo are registered trademarks of the Norgine group of companies.
 Fischbach W, et al. Cost consequence model investigating the impact of bowel cleansing on prevention of colorectal cancer in a German screening population. ISPOR 17th Annual European Congress 2014 abstract #PCN97
 Pohl J, et al. A multicentre, randomised, investigator-blinded study (MODEC) comparing the cleansing quality and the observed lesion detection rate of two bowel preparations: 2L Polyethylene Glycol with Electrolytes + Ascorbate Components (:PEG+ASC) and Sodium Picosulfate/Magnesium Citrate (NaPic/MgCit). ACG Annual Scientific Meeting 2014 abstract
 Kaatsch P, et al. Cancer in Germany 2007/2008, 8th edition 2012.
 West NJ, et al. Colorectal cancer screening in Europe: differences in approach; similar barriers to overcome. Int J Colorectal Dis 2009:24:731-740
 Rex DK, et al. Gastroenterology 1997:112:24-28